Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of NC-2800 in healthy adult male volunteers
jRCT2071210033Phase 1Completed
- Sponsor
- Nippon Chemiphar
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, double-blind trial of NC-2800 in major depressive disorder (MDD) (4 arms), sponsored by Nippon Chemiphar. Primary endpoints: Incidence rate of adverse events, Incidence rate of adverse reactions and 6 more. Started Jul 2021; status: completed.
02
Drugs
NC-2800
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2071210033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210033.